Position in NVS
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$761,815
+$213,137 QoQ
Shares Held
4,861
+35.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#716
of 1,603 holders
Holding Since
Dec 2020
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026RFG Advisory, LLC holds $46,810,911 across 13 Drug Manufacturers - General names. NVS ranks #11 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
10,775 | $12,923,859 | |
| 2 | ABBV |
AbbVie Inc.
|
40,584 | $10,212,557 | |
| 3 | JNJ |
Johnson & Johnson
|
22,980 | $5,836,230 | |
| 4 | AMGN |
Amgen Inc
|
14,031 | $5,080,905 | |
| 5 | NVO |
Novo Nordisk A S
|
66,135 | $3,170,511 | |
| 6 | MRK |
Merck & Co., Inc.
|
20,666 | $2,655,581 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
35,462 | $2,043,320 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
12,955 | $1,636,734 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $761,815 | 4,861 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $548,678 | 3,592 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $311,999 | 2,263 | Shares | Sole | 2026-02-03 | |
| 2024-12-31 | $838,520 | 8,617 | Shares | Sole | 2025-01-21 | |
| 2024-09-30 | $1,376,444 | 11,967 | Shares | Sole | 2024-10-17 | |
| 2020-12-31 | $203,213 | 2,152 | Shares | Sole | 2021-02-02 | |
| No filing history on record for this holder in this stock. | ||||||